Alberto C S Costa

List of Publications by Year
in descending order

57	2,261	304368	223531
papers	citations	22 h-index	46 g-index

60	60	60	2622
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Sustained hippocampal IL-1Î² overexpression impairs contextual and spatial memory in transgenic mice. Brain, Behavior, and Immunity, 2010, 24, 243-253.	2.0	197
2	Deficits in hippocampal CA1 LTP induced by TBS but not HFS in the Ts65Dn mouse: A model of Down syndrome. Neuroscience Letters, 2005, 382, 317-322.	1.0	164
3	Acute Injections of the NMDA Receptor Antagonist Memantine Rescue Performance Deficits of the Ts65Dn Mouse Model of Down Syndrome on a Fear Conditioning Test. Neuropsychopharmacology, 2008, 33, 1624-1632.	2.8	160
4	Motor dysfunction in a mouse model for Down syndrome. Physiology and Behavior, 1999, 68, 211-220.	1.0	155
5	Down syndrome and genetics â€" a case of linked histories. Nature Reviews Genetics, 2005, 6, 137-147.	7.7	144
6	Fluoxetine rescues deficient neurogenesis in hippocampus of the Ts65Dn mouse model for Down syndrome. Experimental Neurology, 2006, 200, 256-261.	2.0	130
7	Gait dynamics in trisomic mice: quantitative neurological traits of Down syndrome. Physiology and Behavior, 2004, 82, 381-389.	1.0	109
8	Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial. Translational Psychiatry, 2012, 2, e141-e141.	2.4	86
9	Human Sensory Neurons Derived from Induced Pluripotent Stem Cells Support Varicella-Zoster Virus Infection. PLoS ONE, 2012, 7, e53010.	1.1	83
10	Experimental parameters affecting the Morris water maze performance of a mouse model of Down syndrome. Behavioural Brain Research, 2004, 154, 1-17.	1.2	79
11	Medical vulnerability of individuals with Down syndrome to severe COVID-19â€"data from the Trisomy 21 Research Society and the UK ISARIC4C survey. EClinicalMedicine, 2021, 33, 100769.	3.2	73
12	Prospects for Improving Brain Function in Individuals with Down Syndrome. CNS Drugs, 2013, 27, 679-702.	2.7	69
13	Behavioral validation of the Ts65Dn mouse model for Down syndrome of a genetic background free of the retinal degeneration mutation Pde6brd1. Behavioural Brain Research, 2010, 206, 52-62.	1.2	65
14	The proteins of human chromosome 21. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2006, 142C, 196-205.	0.7	59
15	Molecular responses of the Ts65Dn and Ts1Cje mouse models of Down syndrome to MKâ€801. Genes, Brain and Behavior, 2008, 7, 810-820.	1.1	56
16	Exaggerated NMDA mediated LTD in a mouse model of Down syndrome and pharmacological rescuing by memantine. Learning and Memory, 2011, 18, 774-778.	0.5	54
17	Genetic analysis of Down syndrome-associated heart defects in mice. Human Genetics, 2011, 130, 623-632.	1.8	47
18	Soluble prion protein and its N-terminal fragment prevent impairment of synaptic plasticity by AÎ² oligomers: Implications for novel therapeutic strategy in Alzheimer's disease. Neurobiology of Disease, 2016, 91, 124-131.	2.1	40

#	Article	IF	Citations
19	G-Protein-Gated Potassium (GIRK) Channels Containing the GIRK2 Subunit Are Control Hubs for Pharmacologically Induced Hypothermic Responses. Journal of Neuroscience, 2005, 25, 7801-7804.	1.7	35
20	On the Promise of Pharmacotherapies Targeted at Cognitive and Neurodegenerative Components of Down Syndrome. Developmental Neuroscience, 2011, 33, 414-427.	1.0	33
21	Generation of Integration-Free Induced Pluripotent Stem Cells from Urine-Derived Cells Isolated from Individuals with Down Syndrome. Stem Cells Translational Medicine, 2017, 6, 1465-1476.	1.6	33
22	Protein Dynamics Associated with Failed and Rescued Learning in the Ts65Dn Mouse Model of Down Syndrome. PLoS ONE, 2015, 10, e0119491.	1.1	31
23	The Mouse Model of Down Syndrome Ts65Dn Presents Visual Deficits as Assessed by Pattern Visual Evoked Potentials. , 2010, 51, 3300.		25
24	COVID-19 in Children with Down Syndrome: Data from the Trisomy 21 Research Society Survey. Journal of Clinical Medicine, 2021, 10, 5125.	1.0	24
25	Editing of the serotonin 2C receptor pre-mRNA: Effects of the Morris Water Maze. Gene, 2007, 391, 186-197.	1.0	22
26	Mouse Models of down Syndrome. , 1999, , 297-327.		22
27	An assessment of the vestibulo-ocular reflex (VOR) in persons with Down syndrome. Experimental Brain Research, 2011, 214, 199-213.	0.7	21
28	Ultrasonic vocalizations during maleâ€“female interaction in the mouse model of Down syndrome Ts65Dn. Physiology and Behavior, 2014, 128, 119-125.	1.0	19
29	Deletion of the Glutamate Receptor 5 Subunit of Kainate Receptors Affects the Development of Morphine Tolerance. Journal of Pharmacology and Experimental Therapeutics, 2009, 328, 579-587.	1.3	17
30	Treatment of Alzheimer disease in Down syndrome. Nature Reviews Neurology, 2012, 8, 182-184.	4.9	15
31	Protein Profiles Associated With Context Fear Conditioning and Their Modulation by Memantine. Molecular and Cellular Proteomics, 2014, 13, 919-937.	2.5	15
32	High resolution structural and functional MRI of the hippocampus in young adults with Down syndrome. Brain Communications, 2021, 3, fcab088.	1.5	15
33	Cross-Sectional Exploration of Plasma Biomarkers of Alzheimerâ€™s Disease in Down Syndrome: Early Data from the Longitudinal Investigation for Enhancing Down Syndrome Research (LIFE-DSR) Study. Journal of Clinical Medicine, 2021, 10, 1907.	1.0	15
34	The Glutamatergic Hypothesis for Down Syndrome: The Potential Use of N-Methyl-D-Aspartate Receptor Antagonists to Enhance Cognition and Decelerate Neurodegeneration. CNS and Neurological Disorders - Drug Targets, 2014, 13, 16-25.	0.8	14
35	On the Design of Broad-Based Neuropsychological Test Batteries to Assess the Cognitive Abilities of Individuals with Down Syndrome in the Context of Clinical Trials. Brain Sciences, 2018, 8, 205.	1.1	14
36	Safety, efficacy, and tolerability of memantine for cognitive and adaptive outcome measures in adolescents and young adults with Down syndrome: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurology, The, 2022, 21, 31-41.	4.9	13

#	Article	IF	Citations
37	Machine Learning Methods Predict Locomotor Response to MK-801 in Mouse Models of Down Syndrome. Journal of Neurogenetics, 2011, 25, 40-51.	0.6	12
38	Pharmacological Modulation of Three Modalities of CA1 Hippocampal Long-Term Potentiation in the Ts65Dn Mouse Model of Down Syndrome. Neural Plasticity, 2018, 2018, 1-14.	1.0	12
39	Hypothermic responses to 8-OH-DPAT in the Ts65Dn mouse model of Down syndrome. NeuroReport, 2006, 17, 837-841.	0.6	9
40	An assessment of optokinetic nystagmus (OKN) in persons with down syndrome. Experimental Brain Research, 2011, 214, 381-391.	0.7	9
41	Pharmacokinetic Properties of Memantine after a Single Intraperitoneal Administration and Multiple Oral Doses in Euploid Mice and in the Ts65Dn Mouse Model of Down's Syndrome. Basic and Clinical Pharmacology and Toxicology, 2017, 121, 382-389.	1.2	9
42	COVID-19 Vaccination of Individuals with Down Syndromeâ€”Data from the Trisomy 21 Research Society Survey on Safety, Efficacy, and Factors Associated with the Decision to Be Vaccinated. Vaccines, 2022, 10, 530.	2.1	8
43	Deletion of the GluR5 subunit of kainate receptors affects cocaine sensitivity and preference. Neuroscience Letters, 2010, 468, 186-189.	1.0	6
44	5-HT1A Receptor Null Mutant Mice Responding Under a Differential-Reinforcement-of-Low-Rate 72-Second Schedule of Reinforcement. The Open Neuropsychopharmacology Journal, 2008, 1, 24-32.	0.3	6
45	Novel DYRK1A Inhibitor Rescues Learning and Memory Deficits in a Mouse Model of Down Syndrome. Pharmaceuticals, 2021, 14, 1170.	1.7	6
46	Evidence of Energy Metabolism Alterations in Cultured Neonatal Astrocytes Derived from the Ts65Dn Mouse Model of Down Syndrome. Brain Sciences, 2022, 12, 83.	1.1	5
47	Atypical electrophysiological and behavioral responses to diazepam in a leading mouse model of Down syndrome. Scientific Reports, 2021, 11, 9521.	1.6	3
48	Intracellular chloride accumulation: a possible mechanism for cognitive deficits in Down syndrome. Nature Medicine, 2015, 21, 312-313.	15.2	2
49	Quantitative Analysis of Retinal Structure and Function in Two Chromosomally Altered Mouse Models of Down Syndrome. , 2020, 61, 25.		2
50	Noninvasive assessment of autonomic modulation of heart rate variability in the Ts65Dn mouse model of Down syndrome: A proof of principle study. Physiological Reports, 2020, 8, e14486.	0.7	1
51	Microcapillary Reactors via Coaxial Electrospinning: Fabrication of Small Poly(Acrylic Acid) Gel Beads and Thin Threads of Biological Cell Dimensions. Gels, 2021, 7, 37.	2.1	1
52	Bio-Mimicking, Electrical Excitability Phenomena Associated With Synthetic Macromolecular Systems: A Brief Review With Connections to the Cytoskeleton and Membraneless Organelles. Frontiers in Molecular Neuroscience, 2022, 15, 830892.	1.4	1
53	Ts65Dn: un modÃ¨le murin du syndrome de Down. Annales De L'Institut Pasteur / ActualitÃ©s, 1998, 9, 321-336.	0.1	0
54	TRANSLATIONAL MEDICINE AT THE INTERSECTION OF EVIDENCE-BASED MEDICINE AND NARRATIVE MEDICINE. Journal of Human Growth and Development, 2015, 25, 253.	0.2	0

#	Article	IF	Citations
55	Hippocampal subfield volume differences are independent of age in teenagers and young adults with Down syndrome. Alzheimer's and Dementia, 2020, 16, e040460.	0.4	0
56	Effects of Memantine on NMDA Induced Longâ€Term Depression in Mouse Models of Down Syndrome. FASEB Journal, 2009, 23, .	0.2	0
57	P2â€030: THE LIFEâ€DSR STUDY. Alzheimer's and Dementia, 2019, 15, .	0.4	0